Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Kwon, Brian-Yong S. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000
Reexamination Certificate
active
07098237
ABSTRACT:
A composition for treating or preventing ischemia reperfusion injury which contains an sPLA2inhibitor as an active ingredient.
REFERENCES:
patent: 5648331 (1997-07-01), Koudsi et al.
patent: 5654326 (1997-08-01), Bach et al.
patent: 5733916 (1998-03-01), Neely
patent: 5986106 (1999-11-01), Khau et al.
patent: 6214855 (2001-04-01), Gemba et al.
patent: 0 620 214 (1994-10-01), None
patent: 0 620 215 (1994-10-01), None
patent: 0 672 415 (1995-02-01), None
patent: 0 675 110 (1995-04-01), None
patent: 1 085 021 (2001-03-01), None
patent: WO 96/03120 (1996-02-01), None
patent: WO 96/03376 (1996-02-01), None
patent: WO 96/03383 (1996-02-01), None
patent: WO 97/21664 (1997-06-01), None
patent: WO 97/21716 (1997-06-01), None
patent: WO 98/18464 (1998-05-01), None
patent: WO 98/24437 (1998-06-01), None
patent: WO 98/24756 (1998-06-01), None
patent: WO 98/24794 (1998-06-01), None
patent: WO 98/25609 (1998-06-01), None
patent: WO 99/51605 (1999-10-01), None
patent: WO 99/59999 (1999-11-01), None
“Preconditioning Protects Against Ischemia-Reperfusion Injury of The Liver”, Nilsson, abstract, Digestive Disease Week, 1998.
Jennifer Daley et al, “Validating Risk-Adjusted Surgical Outcomes: Site Visit Assessment of Process and Structure”, J. Am. Coll. Sugr., 185(4):353-364 (1997), Elsevier Science, Inc.
Satoru Todo et al., “Attenuation of Ischemic Liver Injury by Augmentation of Endogenous Adenosine”, Transplantation, 63(2):217-223 (1997), Williams & Wilkins.
Naoki Ishizaki et al. “Comparison of Various Lazaroid Compounds for Protection Against Ischemic Liver Injury”, Transplantation, 63(2):202-208 (1997), Williams & Wilkins.
Kaoru Koike et al, “Intestinal Ischemia and Type II Phospholipase A2: Preliminary Report”, Department of Emergency and Critical Care Medicine , Japan , p. 823(1995).
Kaoru Koike et al., “Intestinal Ischemia and Tyoe II Phospholipase A2: Preliminary Report”, Japan, p. 823 (1995).
Roberta E. Sonnino et al, “Phospholipase A2Secretion During Intestinal Graft Ischemia”, Digestive Diseases and Sciences, 42(5):972-981 (1997) Plenum Publishing Corporation.
Leon J. De Windt et al., “Phospholipase A2-mediated Hydrolysis of Cardiac Phospholipids: The use of Molecular and Transgenic Techniques”, Molecular and Cellular Biochemistry 180:65-73 (1998) Kluwer Academic Publishers, printed in the Netherlands.
Jun Takasaki et al., “Antibodies Against Type II Phospholipase A2Prevent Renal Injury Due to Ischemia and Reperfusion in Rats”, FEBS Letters, 440:377-381 (1998) Federation of European Biochemical Societies.
Carol A. Sargent et al., “Effect of the Phospholilphase A2Inhibitors Quinacrine and 7,7- Dimethyleicosadienoic Acid in Isolated Globaly Ischemic Rat Hearts”, The Journal of Pharmacology and Experimental Therapeutics, 262(3):1161-1167 (1992), The American Society for Pharmacology and Experimental Therapeutics.
Yoshiro Shimizu, “Nafamostat Mesilate Rinse Solution—A New Strategy To Prevent Warm Ischemia- Reperfusion Injury In Canine Pancreas Autotransplantation”, J. Kyoto Pref. Univ. Med. 107(4), pp. 483-497 (1998).
Foley & Lardner LLP
Kwon Brian-Yong S.
Shionogi & Co. Ltd.
LandOfFree
Remedies for ischemia reperfusion injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedies for ischemia reperfusion injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedies for ischemia reperfusion injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628680